Sangamo Therapeutics (FRA:GBY) Moat Score: 5/10 (As of Aug. 12, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Sangamo Therapeutics Moat Score?

Sangamo Therapeutics FRA:GBY Moat Score is 5 as of Aug. 12, 2026. The stock has 5 warning signs investors should review. Among 1,388 Biotechnology companies, Sangamo Therapeutics ranks better than 96.69% on this metric.

Sangamo Therapeutics has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

Sangamo Therapeutics has Narrow Moat: Sangamo Therapeutics Inc has a solid narrow moat due to its valuable intellectual property and patents in gene therapy. The company benefits from consistent R&D capabilities and moderate regulatory barriers, but faces competition from larger biotech firms, limiting its moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Sangamo Therapeutics might have Narrow Moat - Solid narrow moat.

Sangamo Therapeutics  (FRA:GBY) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Sangamo Therapeutics Moat Score Related Terms

FRA:GBY vs SER, ABVC, PLRZ: Moat Score Comparison

For the Biotechnology subindustry, Sangamo Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sangamo Therapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sangamo Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where Sangamo Therapeutics's Moat Score falls into.


Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
Sangamo Therapeutics (FRA:GBY) has a Moat Score of 5 as of Aug. 12, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Sangamo Therapeutics ranks #46 out of 1388 companies in the Biotechnology industry, placing it in the top 3.3%.
Is Sangamo Therapeutics' Moat Score too high?
Sangamo Therapeutics' current Moat Score is 5. The Biotechnology industry median Moat Score is 2.00. Sangamo Therapeutics' value of 5 is 150% above this industry median. Based on the distribution chart, Sangamo Therapeutics ranks #46 out of 1388 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Sangamo Therapeutics' Moat Score compare to SER and ABVC?
According to the Biotechnology industry distribution chart, Sangamo Therapeutics ranks #46 out of 1388 companies for Moat Score. This places Sangamo Therapeutics in the top 3% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Sangamo Therapeutics' value of 5 is 150% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,388 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sangamo Therapeutics's current Moat Score of 5 is 150% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sangamo Therapeutics's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sangamo Therapeutics stock overvalued right now?
Sangamo Therapeutics (FRA:GBY) has a current Moat Score of 5. The stock's GF Value™ is €0.18, compared to a current price of €0.07 — trading 63.2% below its estimated fair value. The current Moat Score is 5 and 150% above the Biotechnology industry median of 2.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Sangamo Therapeutics (FRA:GBY), the current Moat Score is 5 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sangamo Therapeutics Business Description

Other Exchanges SGMO:USA0R1D:UKGBY:Germany
Address 501 Canal Boulevard, Richmond, CA, USA, 94804
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its neurology development is focused on two areas: development of epigenetic regulation therapies to treat serious neurological diseases and development of novel engineered adeno-associated virus, or AAV, capsids to deliver its therapies to the intended neurological targets. The group's pipeline products are Small Fiber Neuropathy, Prion Disease, Tauopathies, ALS/FTD, Huntington's Disease, Fabry Disease, and Hemophilia A.